Skip to main content
. Author manuscript; available in PMC: 2010 Mar 16.
Published in final edited form as: Cell Prolif. 2006 Aug;39(4):261–279. doi: 10.1111/j.1365-2184.2006.00388.x

Figure 6. EGF-induced G2-phase arrest requires ERK activity.

Figure 6

Cells synchronized at the G1/S boundary were released back into the cell cycle and treated with EGF (100 ng/ml, 7 h after G1/S release), U0126 (10 µm, 6.5 h after G1/S release), or both EGF and U0126. (a) Immunoblots show the levels of ppERK1/2 (top panel), cyclin B1 (middle panel) and α-tubulin (lower panel) as a protein loading control. (b) The MI at varying times after G1/S release in untreated (white bars), EGF-treated (black bars), U0126-treated (checkered bars), or EGF- and U0126-treated cells (grey bars). Data represent the mean and standard error from three independent experiments.